Gilead is licensing nine generic drug companies to make remdesivir to boost supplies of the investigational COVID-19 drug, according to a statement on the company’s website dated Monday (June 22). In the statement, Gilead Chair and CEO Daniel O’Day says he expects to make more than 2 million courses of remdesivir available by the end of the year and “many millions more” by 2021. The company already donated its existing supplies of remdesivir through June, O’Day notes. Gilead donated 940,000...